Diverse prenatal patient populations, including triplet and multiple gestation pregnancies, can only be screened using a single cfDNA screening test, Labcorp's MaterniT® 21 PLUS.

Labcorp's MaterniT 21 PLUS enables cfDNA screening across all pregnant patient populations, including those with triplet and multiple gestation pregnancies. It is the only U.S.-based prenatal cfDNA screening test with this capability.

A recent retrospective study evaluated the use of Labcorp's MaterniT 21 PLUS in triplet pregnancies. Findings suggest that cfDNA screening with MaterniT 21 PLUS in triplet pregnancies shows performance characteristics comparable to those observed in twin pregnancies.